TransMedics (TMDX) Q2 FY26 earnings call

TransMedics delivered record Q2 FY26 revenue, driven by strong OCS case volume and clinical services, particularly in logistics. The company is aggressively investing in four strategic growth initiatives—heart/lung expansion, OCS Kidney development, European market entry, and the next-gen OCS platform—to achieve over $2 billion in annual revenue by 2032, prioritizing long-term growth over near-term operating leverage.